Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Hale

Showing results (111-120 of 135) with videos related to

Pageof 14
Sort By:
Clinical Immunology (Orlando, Fla.)|July 21, 2018
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial designDoreen O Jackson, Francois A Trappey, G Travis Clifton, et al.
Immunotherapy|February 24, 2018
Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccineMark O Hardin, Timothy J Vreeland, Guy T Clifton, et al.
Vaccine|May 5, 2018
Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumorsGarth S Herbert, Timothy J Vreeland, Guy T Clifton, et al.
Journal of Cancer|September 14, 2017
Routine Pre-Treatment MRI for Breast Cancer in a Single-Payer Medical Center: Effects on Surgical Choices, Timing and OutcomesTimothy J Vreeland, John S Berry Iv, Erika Schneble, et al.
Clinical Immunology (Orlando, Fla.)|March 26, 2018
Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune responseTimothy J Vreeland, Jennifer K Litton, Na Qiao, et al.
Cancer Immunology, Immunotherapy : CII|November 12, 2020
Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreementPhillip M Kemp Bohan, Robert C Chick, Annelies T Hickerson, et al.
Cell Reports|April 23, 2026
Unmasking pathogen traits for chronic colonization in neurogenic bladderSeth A Reasoner, Brendan T Frainey, Owen F Hale, et al.
Biorxiv : the Preprint Server for Biology|August 20, 2025
Unmasking Pathogen Traits for Chronic Colonization in Neurogenic Bladder PatientsSeth A Reasoner, Brendan T Frainey, Owen F Hale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrenceE A Mittendorf, A Ardavanis, J Symanowski, et al.
Frontiers in Systems Neuroscience|February 15, 2021
Alterations of Spinal Epidural Stimulation-Enabled Stepping by Descending Intentional Motor Commands and Proprioceptive Inputs in Humans With Spinal Cord InjuryMegan L Gill, Margaux B Linde, Rena F Hale, et al.
Pageof 14

Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
Clinical Immunology (Orlando, Fla.)|July 21, 2018
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial designDoreen O Jackson, Francois A Trappey, G Travis Clifton, et al.
Immunotherapy|February 24, 2018
Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccineMark O Hardin, Timothy J Vreeland, Guy T Clifton, et al.
Vaccine|May 5, 2018
Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumorsGarth S Herbert, Timothy J Vreeland, Guy T Clifton, et al.
Journal of Cancer|September 14, 2017
Routine Pre-Treatment MRI for Breast Cancer in a Single-Payer Medical Center: Effects on Surgical Choices, Timing and OutcomesTimothy J Vreeland, John S Berry Iv, Erika Schneble, et al.
Clinical Immunology (Orlando, Fla.)|March 26, 2018
Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune responseTimothy J Vreeland, Jennifer K Litton, Na Qiao, et al.
Cancer Immunology, Immunotherapy : CII|November 12, 2020
Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreementPhillip M Kemp Bohan, Robert C Chick, Annelies T Hickerson, et al.
Cell Reports|April 23, 2026
Unmasking pathogen traits for chronic colonization in neurogenic bladderSeth A Reasoner, Brendan T Frainey, Owen F Hale, et al.
Biorxiv : the Preprint Server for Biology|August 20, 2025
Unmasking Pathogen Traits for Chronic Colonization in Neurogenic Bladder PatientsSeth A Reasoner, Brendan T Frainey, Owen F Hale, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 2016
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrenceE A Mittendorf, A Ardavanis, J Symanowski, et al.
Frontiers in Systems Neuroscience|February 15, 2021
Alterations of Spinal Epidural Stimulation-Enabled Stepping by Descending Intentional Motor Commands and Proprioceptive Inputs in Humans With Spinal Cord InjuryMegan L Gill, Margaux B Linde, Rena F Hale, et al.
Pageof 14